EN | TR
E-ISSN: 3061-9947
Platinum-based Regimens in First-line Therapy of Non-Small Cell Lung Cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 1
P: 102-107
2020

Platinum-based Regimens in First-line Therapy of Non-Small Cell Lung Cancer

Acta Haematol Oncol Turc 2020;53(1):102-107
DOI: 10.5505/aot.2020.43108
Abdulkadir Karışmaz 1
Mustafa Sevinc 2
Murat Tugcu 3
Fuat Hulusi Demirelli 4
Hande Turna 4
1. Department of Hematology. Istanbul Training and Research Hospital, Istanbul, Turkey
2. Nephrology Departmant, Sisli Hamidiye Etfal Training And Research Hospital, Istanbul, Turkey
3. Department Of Nephrology, Marmara University Pendik Training And Research Hospital, Istanbul, Turkey.
4. Department Of Oncology, Cerrahpasa Faculty Of Medicine, Istanbul University - Cerrahpasa, Istanbul, Turkey
5.
No information available.
No information available
Received Date: 2019-08-19T23:53:19
Accepted Date: 2020-04-28T11:20:11
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Lung cancer is the leading cause of cancer-related death in both men and women. If there is no EGFR, ALK and ROS1 mutation in patients with metastatic NSCLC (non-small cell lung cancer), the standard treatment is a platinum-based combination regimen. The choice of agent combined with platinum is generally determined by considering the toxicity profile of the drug and the tolerance of the patient. In this study, we aimed to determine the response rates, progression-free survival and overall survival in patients with metastatic NSCLC with first-line systemic chemotherapy according to different histological subtypes.

METHODS

The files of totally 300 patients 62 of whom were female and followed with the diagnosis of Stage IV Non-Small Cell Lung Cancer in the Clinic of Medical Oncology of Cerrahpaşa Medical Faculty were investigated retrospectively between 2005 and 2010. Types of first line chemotherapy, the number of cures, treatment response rates, time to progression and overall survival times were determined.

RESULTS

Median time to progression after first line chemotherapy for all the cases was detected as 5 weeks. In the cases with squamous cell cancer, no significant superiority was detected in terms of time to progression with different regimens. In the cases with adenocarcinoma, Cisplatin-Docetaxel combination was found to provide a significant superiority to the Cisplatin-Gemcitabine combination in terms of time to progression.

DISCUSSION AND CONCLUSION

We are currently evaluating molecular tests for the treatment of stage 4 NSCLC. If there is no EGFR, ALK and ROS 1 mutation, we use systemic cytotoxic chemotherapy regimens. These regimens are platinum-based. There was no difference between the regimens in squamous cell carcinoma when the time to progression of the agents to be given to platinum first step was taken into consideration. Cisplatin - docetaxel combination was found to be more effective in adenocarcinoma.